Beckman Coulter and Ortho Clinical Partner to Deliver Infectious Disease Testing Menu
By LabMedica International staff writers Posted on 04 Jul 2016 |
Beckman Coulter, Inc., (Brea, California, USA) and Ortho Clinical Diagnostics (Raritan, New Jersey, USA) have entered a strategic relationship for marketing Ortho's VITROS 3600 Immunodiagnostic System and infectious disease menu in the United States.
Ortho's VITROS 3600 System combines three high-quality proprietary technologies into a single self-monitoring system and offers a broad menu of infectious disease tests that are used by a number of leading reference laboratories in the United States. Beckman Coulter will place the VITROS 3600 System running HIV and hepatitis assays in labs that currently run its Power Processor Sample Handling Systems, and other very high-volume laboratories. This will allow very high-volume laboratories to access state-of-the-art infectious disease testing on the VITROS 3600 System and help them improve operational efficiency as well as patient care.
Beckman Coulter and Ortho will also collaborate to obtain clearance/approval from the U.S. Food and Drug Administration to connect the VITROS 3600 System to the Power Processor to run infectious disease tests.
"We look forward to working with the impressive team at Ortho to bring Ortho's high-quality infectious disease testing to our customers," said John Nosenzo, senior vice president, Customer Operations, Developed Markets at Beckman Coulter. "This relationship provides both immediate opportunity and long-term value as we continue to enhance efficiency, advance patient care and broaden our customer offerings. Through this relationship, we will be able to apply innovative technologies to deliver enhanced solutions to the highest-volume labs in the U.S."
"Ortho has long been a pioneer in infectious disease testing. Our relationship with Beckman will help us deliver that expertise to their large installed base of automated labs," said Alex Socarrás, executive vice president, Global Commercial Operations at Ortho. "We are committed to forming key strategic collaborations such as this one, which enable us to stay focused on our core business while being nimble enough to meet the varied and changing needs of our valued customers."
Related Links:
Beckman Coulter
Ortho Clinical Diagnostics
Ortho's VITROS 3600 System combines three high-quality proprietary technologies into a single self-monitoring system and offers a broad menu of infectious disease tests that are used by a number of leading reference laboratories in the United States. Beckman Coulter will place the VITROS 3600 System running HIV and hepatitis assays in labs that currently run its Power Processor Sample Handling Systems, and other very high-volume laboratories. This will allow very high-volume laboratories to access state-of-the-art infectious disease testing on the VITROS 3600 System and help them improve operational efficiency as well as patient care.
Beckman Coulter and Ortho will also collaborate to obtain clearance/approval from the U.S. Food and Drug Administration to connect the VITROS 3600 System to the Power Processor to run infectious disease tests.
"We look forward to working with the impressive team at Ortho to bring Ortho's high-quality infectious disease testing to our customers," said John Nosenzo, senior vice president, Customer Operations, Developed Markets at Beckman Coulter. "This relationship provides both immediate opportunity and long-term value as we continue to enhance efficiency, advance patient care and broaden our customer offerings. Through this relationship, we will be able to apply innovative technologies to deliver enhanced solutions to the highest-volume labs in the U.S."
"Ortho has long been a pioneer in infectious disease testing. Our relationship with Beckman will help us deliver that expertise to their large installed base of automated labs," said Alex Socarrás, executive vice president, Global Commercial Operations at Ortho. "We are committed to forming key strategic collaborations such as this one, which enable us to stay focused on our core business while being nimble enough to meet the varied and changing needs of our valued customers."
Related Links:
Beckman Coulter
Ortho Clinical Diagnostics
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance